Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Successful merger with Lung Therapeutics providing a focused pipeline of clinical-stage candidates
- Lead product candidate LTI-03 expected to report topline results in the third quarter of 2024
- Cash runway anticipated to fund operations and key milestones through the fourth quarter of 2024
- Appointment of Brian Windsor, Ph.D., as President and CEO and to the Board of Directors
- LTI-03's dual mechanism of action gaining support from the medical community
- Financial results show a decrease in R&D expenses and an increase in G&A expenses
- Net loss increased in the fourth quarter of 2023 compared to the same period in 2022
- Cash, cash equivalents, and investments decreased from December 31, 2022, to December 31, 2023
The liquidity position of Aileron Therapeutics, with $17.3 million in cash and equivalents at the end of 2023, suggests a prudent cash management strategy. This is particularly noteworthy given the burn rate reflected in the reported R&D and G&A expenses. The reduction in R&D expenses, from $18.0 million in the full-year 2022 to $4.0 million in 2023, indicates a strategic pivot or scaling back of development activities, likely aligning with the company's focus on prioritizing its lung disease pipeline post-acquisition. The increased G&A expenses from $9.7 million in full-year 2022 to $11.4 million in full-year 2023 demonstrate the costs associated with integrating Lung Therapeutics.
From an investor's perspective, the net loss widening from $4.5 million in Q4 2022 to $7.3 million in Q4 2023 raises concerns about profitability and sustainability. Still, the lower loss per share from the full-year perspective ($3.42 in 2023 vs. $6.02 in 2022) could indicate an improved financial discipline or impact from the recent financial transaction. Shareholders need to consider the company's strategy to manage expenditures and their expectations for revenue generation, especially with the upcoming clinical trial results.
The advancement of LTI-03 and LTI-01 into later stages of clinical trials is a critical juncture for Aileron. LTI-03's dual mechanism of action targeting both epithelial cells and fibroblasts could represent a significant therapeutic advance for idiopathic pulmonary fibrosis (IPF), a condition with limited treatment options. The specific targeting of Caveolin-1-related pathways reveals Aileron's strategic focus on novel drug mechanisms. The anticipation of Phase 1b study results in the next year could serve as a catalyst for increased investor interest, especially if the data aligns with the preclinical findings.
Investors should understand that orphan drug and Fast Track designations for LTI-01 signify both the unmet medical need and the potential for expedited development and review by regulatory agencies. However, the actual impact on the company's valuation will heavily depend on the outcomes of these trials and the regulatory path forward. It is the data from these trials that will inform the true potential of the company's pipeline to satisfy unmet medical needs and drive future revenue.
The biopharmaceutical sector, particularly the orphan drug space Aileron is targeting, is often characterized by high risk but potentially high reward. The acquisition of Lung Therapeutics appears to be a strategic move to strengthen Aileron's position in this niche market. The funds secured through the sale of Series X preferred stock and warrants, led by Bios Partners and Nantahala Capital, enhance the company's financial runway and support its strategic initiatives.
Investors should monitor the evolving competitive landscape for IPF and LPE treatments. Adoption rates, pricing strategy and partnership opportunities post-trial results will be essential factors in assessing Aileron's market potential. The company's collaboration with key opinion leaders, as evidenced by their expert panel discussion, could bode well for market penetration and physician acceptance of their product candidates should they gain approval.
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024
Cash runway expected to fund operations and key milestones into the fourth quarter of 2024
AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
“We ended the year in a solid position after the successful completion of our merger with Lung Therapeutics, which provided a focused pipeline of promising clinical-stage candidates for life-threatening lung conditions, coupled with a strengthened balance sheet from the successful closure of a
Recent Business Highlights and Upcoming Milestones
Corporate Updates
- In October 2023, Aileron acquired Lung Therapeutics, Inc. (“Lung”), shifting the Company’s disease focus to advance a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases. The Company’s lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).
- Immediately following the closing of Aileron’s acquisition of Lung (“Lung Acquisition”), the Company entered into a definitive agreement for the sale of shares of its Series X non-voting convertible preferred stock and warrants to purchase shares of Aileron common stock in a private placement to a group of accredited investors led by Bios Partners, the majority stockholder of Lung prior to the Lung Acquisition, and including Nantahala Capital, as well as additional undisclosed investors. The private placement resulted in gross proceeds to Aileron of approximately
$18 million before deducting placement agent fees and other offering expenses. - In March 2024, the Company announced the appointment of Brian Windsor, Ph.D., as President and Chief Executive Officer and to the Board of Directors. Dr. Windsor previously served as Aileron’s Chief Operating Officer and President, and Chief Executive Officer and director of Lung.
Pipeline
- In February 2024, Aileron hosted a pulmonary care expert panel to discuss the potential implications of LTI-03 for IPF, featuring pulmonary care experts Fernando J. Martinez, M.D., M.S., Chief of the Pulmonary and Critical Care Medicine Division at Weill Cornell Medicine; Tejaswini Kulkarni, M.D., M.P.H., Associate Professor of Pulmonology, Allergy and Critical Care Medicine and Director of the Interstitial Lung Disease Program at University of Alabama at Birmingham Medicine; and Andreas Günther, M.D., Senior Physician of Pulmonology and Intensive Care Medicine and Chief Physician of Pulmonology and Internal Intensive Care Medicine at Agaplesion Evang. Central Hesse Hospital and Professor of Interstitial and Rare Lung Diseases at Justus Liebig University. A replay of the event can be accessed at https://investors.aileronrx.com/events-presentations/investor-events.
- LTI-03: a novel Caveolin-1-related (Cav1) peptide with a dual mechanism targeting both alveolar epithelial cell survival as well as inhibition of profibrotic signaling
- LTI-03 is currently in a randomized, double-blind, placebo-controlled Phase 1b clinical trial in IPF patients. Aileron expects to report topline results from this trial in the third quarter of 2024.
- LTI-01: a PAI-1 resistant plasmin activated proenzyme for loculated pleural effusions
- LTI-01 has been evaluated in Phase 1b and Phase 2a clinical trials in patients with infected, non-draining LPEs and is ready for Phase 2b. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Fourth Quarter and Full Year 2023 Financial Results
- Cash Position: Cash, cash equivalents, and investments on December 31, 2023, were
$17.3 million , compared to$21.2 million on December 31, 2022. Based on its current operating plan, the Company expects its existing cash, cash equivalents, and investments will fund operations into the fourth quarter of 2024. - Research and Development (R&D) Expenses: R&D expenses for the quarter ended December 31, 2023, were
$2.0 million , compared to$2.4 million for the quarter ended December 31, 2022. R&D expenses decreased primarily due to the termination of R&D activities related to ALRN-6924. R&D expenses for the full-year 2023 were$4.0 million , compared to$18.0 million for the prior year. - General and Administrative (G&A) Expenses: G&A expenses for the quarter ended December 31, 2023, were
$5.3 million compared to$2.3 million for the quarter ended December 31, 2022. G&A expenses increased due to the integration and operating activities of Lung. G&A expenses for the full-year 2023 were$11.4 million , compared to$9.7 million for the prior year. - Net Loss: Net loss for the quarter ended December 31, 2023, was
$7.3 million , compared to$4.5 million for the quarter ended December 31, 2022. The basic and diluted net loss per share for the quarter ended December 31, 2023 was$1.54 compared to$1.00 for the quarter ended December 31, 2022. The basic and diluted net loss per share for the full-year 2023 was$3.42 compared to$6.02 for the full-year 2022.
About Aileron Therapeutics
Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Forward-Looking Statements
This press release may contain forward-looking statements of Aileron within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the timing and expectation of the topline results of the Phase 1b study of LTI-03; future expectations, plans and prospects for the Company following the merger transaction between the Company and Lung that closed in the fourth quarter of 2023 (the “Merger”); the sufficiency of the Company’s cash resources; the projected cash runway of the Company; the status and plans for clinical trials, including the timing of data; future product development; and the potential commercial opportunity of LTI-03 and LTI-01. We use words such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to the ability to recognize the anticipated benefits of the Merger; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in the Company’s drug discovery; preclinical and clinical development activities; the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials; the Company’s ability to enroll patients in its clinical trials; and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the U.S. Food and Drug Administration and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to the Company’s development candidates; our ability to obtain, maintain and enforce intellectual property rights for our platform and development candidates; our potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of the Company’s cash resources to fund its planned activities for the periods anticipated and the Company’s ability to manage unplanned cash requirements; and general economic and market conditions; as well as the risks and uncertainties discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which is on file with the United States Securities and Exchange Commission and in subsequent filings that the Company files with the Securities and Exchange Commission. These forward-looking statements should not be relied upon as representing the Company’s view as of any date subsequent to the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations & Media Contact:
Argot Partners
aileron@argotpartners.com
212-600-1902
| Aileron Therapeutics, Inc. | ||||||||
| Balance Sheet Data | ||||||||
| (Unaudited) | ||||||||
| (In thousands) | ||||||||
| December 31, 2023 | December 31, 2022 | |||||||
| Cash, cash equivalents and investments | $ | 17,313 | $ | 21,242 | ||||
| Working capital | 13,881 | 18,489 | ||||||
| Total assets | 106,008 | 22,007 | ||||||
| Accumulated deficit | (288,517 | ) | (272,785 | ) | ||||
| Total stockholders' equity | 6,887 | 18,623 | ||||||
| Aileron Therapeutics, Inc. | ||||||||||||||||
| Condensed Statement of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue | $ | - | $ | - | $ | - | $ | - | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,972 | 2,402 | 3,991 | 17,967 | ||||||||||||
| General and administrative | 5,330 | 2,301 | 11,357 | 9,680 | ||||||||||||
| Restructuring and other | (12 | ) | - | 928 | - | |||||||||||
| Total Operating expenses | 7,290 | 4,703 | 16,276 | 27,647 | ||||||||||||
| Loss from operations | (7,290 | ) | (4,703 | ) | (16,276 | ) | (27,647 | ) | ||||||||
| Other income (expense), net | (49 | ) | 156 | 544 | 318 | |||||||||||
| Net loss | (7,339 | ) | (4,547 | ) | (15,732 | ) | (27,329 | ) | ||||||||
| Net loss per share — basic and diluted | $ | (1.54 | ) | $ | (1.00 | ) | $ | (3.42 | ) | $ | (6.02 | ) | ||||
| Weighted average common shares outstanding—basic and diluted | 4,769,483 | 4,541,167 | 4,598,715 | 4,539,318 | ||||||||||||
FAQ
What is Aileron Therapeutics' ticker symbol?
When are the topline results from the Phase 1b study of LTI-03 expected?
What is the cash position of Aileron Therapeutics as of December 31, 2023?
Who was appointed as President and CEO of Aileron Therapeutics?
What is the focus of Aileron Therapeutics' lead clinical programs?
